A phase III trial of personalised mRNA therapy intismeran autogene plus pembrolizumab found 82.2% of high-risk melanoma patients were recurrence-free at two years, compared with 70.0%…
Tag: pembrolizumab immunotherapy
Topics related to pembrolizumab immunotherapy.

